Advanced Tumor Clinical Trial
Official title:
A Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumors
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1009 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1009. PM1009 is a new novel fully human anti-TIGIT x PVRIG bispecific antibody, containing a wildtype IgG1 Fc and has high monovalent affinity to each target, it can binds to both TIGIT and PVRIG overexpressing target cells and binds to TIGIT and PVRIG simultaneously.
This is a single-arm, open-label, Phase I study contains dose escalation stage and dose expansion stage. The dose escalation stage will be following the accelerated titration design and the classic 3+3 design, with a planned enrollment of 10 to 24 patients with advanced tumors. The dose expansion stage will be used safe and tolerable doses, with a planned enrollment of 30 patients with advanced tumors. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05108779 -
QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05839106 -
Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02977156 -
Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT00502060 -
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
|
Phase 1 |